He agreed with Dr. Sever and Dr. Lloyd-Jones that the message from ASCOT regarding the use of on-treatment CRP to titrate statin therapy is that it doesn't make sense.
Dr. Sever declared that he is a consultant to and is on the speakers bureau for Pfizer, which sponsored ASCOT. Dr. Cannon is also on the speakers bureau for Pfizer. Dr. Lloyd-Jones reported no relevant financial interests.
'In patients with diabetes, they're on statins. … There's no added benefit to be gained from measuring CRP.'
Source DR. SEVER
ASCOT is just the latest of several studies that ask, 'Is CRP something we need to be spending our time on?'
Source DR. LLOYD-JONES